Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin

Contraception

Volumn 55, Issue 4, 1997, Pages 219-224

  Crook, David ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Desogestrel; Estradiol; Gonadotrophins; Oral contraceptives; Progesterone; Thyroid function

Indexed keywords

CHOLESTEROL; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LIOTHYRONINE; LIPID; LIPOPROTEIN; LUTEINIZING HORMONE; PROLACTIN; THYROGLOBULIN; THYROXINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MIXTURE; ENDOCRINE FUNCTION; ESTRADIOL BLOOD LEVEL; FEMALE; GONADOTROPIN BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MULTICENTER STUDY; ORAL CONTRACEPTION; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; THYROID FUNCTION;

CHOLESTEROL; CHOLESTEROL, HDL; CONTRACEPTIVES, ORAL; DESOGESTREL; ENDOCRINE GLANDS; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYDROCORTISONE; LIPIDS; LIPOPROTEINS; LUTEINIZING HORMONE; PROGESTERONE; THYROXINE; TRIGLYCERIDES; TRIIODOTHYRONINE;

EID: 0030866776     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00010-3     Document Type: Article

References (28)

1. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic diseases and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
2. Sturdevant FM. Safety of oral contraceptives related to steroid content: a critical review. Int J Fertil 1989;34: 323-32.
3. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:672-7.
4. Crook D, Godsland IF, Wynn V. Oral contraception and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol 1988;158:1612-20.
5. Speroff, L, DeCherney A, Burkman RT, et al. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993;81:1034-47.
6. Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 μg ethinyloestradiol and 150 μg desogestrel. Contraception 1995;51:3-12.
7. Van der Vange N. Ovarian activity during low dose oral contraceptives. In: Chamberlain G, ed. Contemporary obstetrics and gynaecology. London: Butterworths, 1988:315-26.
8. Hollander CS, Garcia AM, Sturgis SH, Selenkow HA. Effect of an ovulatory suppressant on the serum protein-bound iodine and the red-cell uptake of radioactive triiodothyronine. New Engl J Med 1963;269:501-4.
9. Meulenberg PMM, Ross HA, Swinkels LMJW, Benraad TJ. The effect of oral contraceptives on plasma-free and salivary Cortisol and cortisone. Clin Chem Acta 1987; 165:379-85.
10. Walling M. A multicenter efficacy and safety study of an oral contraceptive containing 150 μg desogestrel and 30 μg ethinyl estradiol. Contraception 1992;46:313-26.
11. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. Kuhl H, Gahn G, Romberg G, März W, Taubert HD. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception 1985;31:583-8.
13. Dericks-Tan JSE, Gudacker V, Taubert HD. Influence of oral contraceptives on integrated secretion of gonadotropins. Contraception 1992;46:369-77.
14. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 1983;27:577-90.
15. Abu Fadil S, De Vane G, Siler TM, Yen SSC. Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception 1976;13:79-85.
16. Scott JZ, Kletzky OA, Brenner PF, Mishell DR. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function. Fertil Steril 1978;30:141-5.
17. Cullberg G. Androgenic, anabolic, estrogenic and antiestrogenic effects of desogestrel and lynestrenol: effects on serum proteins and vaginal cytology. Contraception 1984;30:73-9.
18. Kuhl H, Gahn G, Romberg G, Althoff PH, Taubert HD. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters: II. Effects upon thyroid function, gastrin, STH, and glucose tolerance. Contraception 1985; 32:97-107.
19. Souma JA, Green PJ, Coppage AT, Donner RS, Hogg AL. Changes in thyroid function in pregnancy and with oral contraceptive use. Southern Med J 1981;74:684-7.
20. Vessey M, Villard-Mackintosh L, McPherson K, Yeates D. Thyroid disorders and oral contraceptives. Br J Fam Plan 1987;13:124-7.
21. Petak SM, Steinberger E. The adrenal gland. In: Goldzieher JW, ed. Pharmacology of the contraceptive steroids. New York: Raven Press, 1994:233-242.
22. Burkman RT. Lipid metabolism with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993; 168:1033-40.
23. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32-47.
24. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-7.
25. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81.
26. Bengttsson C, Bjorklund C, Lapidus L, Lissner L. Assodations of serum lipid concentrations and obesity with mortality in women: 20-year follow-up of participants in prospective population study in Gothenburg, Sweden. Br Med J 1993;307:1385-8.
27. Sacks BW, Walsh FM. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 1993;91:2126-32.
28. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505-10.